Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?

Cancer

Volumn 116, Issue 14, 2010, Pages 3378-3388

  Culp, Stephen H ^a   Tannir, Nizar M ^a   Abel, E Jason ^a   Margulis, Vitaly ^a   Tamboli, Pheroze ^a   Matin, Surena F ^a   Wood, Christopher G ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Cytoreductive nephrectomy; Metastasis; Renal cell carcinoma; Survival

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER CLASSIFICATION; CHI SQUARE TEST; CORRELATION ANALYSIS; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; KIDNEY CARCINOMA; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEPHRECTOMY; OVERALL SURVIVAL; PARAAORTIC LYMPH NODE; PATIENT IDENTIFICATION; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; RISK FACTOR; SYMPTOMATOLOGY;

AGED; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEPHRECTOMY; PATIENT SELECTION; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 77954937811     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25046     Document Type: Article

References (44)

1. American Cancer Society: Cancer Facts and Figures, 2009. Atlanta, Ga: American Cancer Society; 2009.
2. Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr. Rising incidence of renal cell cancer in the United States. JAMA. 1999;281:1628-1631.
3. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis. Cancer. 2007;109:1763-1768.
4. Lam JS, Shvarts O, Leppert JT, Figlin RA, Belldegrun AS. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol. 2005;173:1853-1862.
5. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004;171:1071-1076.
6. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655-1659.
7. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358:966-970.
8. Rini BI, Campbell SC. The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy. J Urol. 2007;177:1978-1984.
9. Fallick ML, McDermott DF, LaRock D, Long JP, Atkins MB. Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J Urol. 1997;158:1691-1695.
10. Greene FL, Page DL, Fleming ID, et al., eds. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag; 2002.
11. Eble J, Sauter G, Epstein J, Sesterhenn I, eds. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press; 2004.
12. Dekernion JB, Ramming KP, Smith RB. The natural history of metastatic renal cell carcinoma: a computer analysis. J Urol. 1978;120:148-152. (Pubitemid 9005387)
13. Montie JE, Stewart BH, Straffon RA, Banowsky LH, Hewitt CB, Montague DK. The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J Urol. 1977;117:272-275.
14. Marcus SG, Choyke PL, Reiter R, et al. Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. J Urol. 1993;150(2 pt 1):463-466.
15. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530-2540.
16. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol. 2000;163:408-417. (Pubitemid 30060482)
17. Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, Krown SE. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol. 1993;11:1368-1375. (Pubitemid 23199143)
18. Muss HB, Costanzi JJ, Leavitt R, et al. Recombinant alfa interferon in renal cell carcinoma: a randomized trial of 2 routes of administration. J Clin Oncol. 1987;5:286-291. (Pubitemid 17021613)
19. Mani S, Todd MB, Katz K, Poo WJ. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers. J Urol. 1995;154:35-40.
20. Rackley R, Novick A, Klein E, Bukowski R, McLain D, Goldfarb D. The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma. J Urol. 1994;152(5 pt 1):1399-1403. (Pubitemid 24326270)
21. Wolf JS Jr, Aronson FR, Small EJ, Carroll PR. Nephrectomy for metastatic renal cell carcinoma: a component of systemic treatment regimens. J Surg Oncol. 1994;55:7-13. (Pubitemid 24048382)
22. Walther MM, Yang JC, Pass HI, Linehan WM, Rosenberg SA. Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J Urol. 1997;158:1675-1678.
23. Levy DA, Swanson DA, Slaton JW, Ellerhorst J, Dinney CP. Timely delivery of biological therapy after cytoreductive nephrectomy in carefully selected patients with metastatic renal cell carcinoma. J Urol. 1998;159:1168-1173.
24. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009;373:1119-1132.
25. Freed SZ. Nephrectomy for renal cell carcinoma with metastases. Urology. 1977;9:613-616.
26. Spencer WF, Linehan WM, Walther MM, et al. Immunotherapy with interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer with in situ primary cancers: a pilot study. J Urol. 1992;147:24-30.
27. Robertson CN, Linehan WM, Pass HI, et al. Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells. J Urol. 1990;144:614-617; discussion 617-618.
28. Rayman P, Wesa AK, Richmond AL, et al. Effect of renal cell carcinomas on the development of type 1 T-cell responses. Clin Cancer Res. 2004;10(18 pt 2):6360S-6366S.
29. Jacobsen J, Rasmuson T, Grankvist K, Ljungberg B. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol. 2000;163:343-347.
30. Leibovich BC, Cheville JC, Lohse CM, et al. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol. 2005;174:1759-1763; discussion 1763.
31. Leibovich BC, Han KR, Bui MH, et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003;98:2566-2575.
32. Suppiah R, Shaheen PE, Elson P, et al. Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer. 2006;107:1793-1800. (Pubitemid 44582948)
33. Choueiri TK, Garcia JA, Elson P, et al. Clinical factors associated with outcome in patients with metastatic clearcell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer. 2007;110:543-550.
34. Fujikawa K, Matsui Y, Oka H, Fukuzawa S, Takeuchi H. Serum C-reactive protein level and the impact of cytoreductive surgery in patients with metastatic renal cell carcinoma. J Urol. 1999;162:1934-1937.
35. Karakiewicz PI, Hutterer GC, Trinh QD, et al. C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients. Cancer. 2007;110:1241-1247.
36. Lee SE, Byun SS, Han JH, Han BK, Hong SK. Prognostic significance of common preoperative laboratory variables in clear cell renal cell carcinoma. BJU Int. 2006;98:1228-1232.
37. Vasselli JR, Yang JC, Linehan WM, White DE, Rosenberg SA, Walther MM. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. J Urol. 2001;166:68-72.
38. Pantuck AJ, Zisman A, Dorey F, et al. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Cancer. 2003;97:2995-3002.
39. Han KR, Pantuck AJ, Bui MH, et al. Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology. 2003;61:314-319.
40. Tatokoro M, Saito K, Iimura Y, Fujii Y, Kawakami S, Kihara K. Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy. J Urol. 2008;180:515-519.
41. Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of nonclear-cell histology. J Clin Oncol. 2002;20:2376-2381.
42. Kassouf W, Sanchez-Ortiz R, Tamboli P, et al. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology. J Urol. 2007;178:1896-1900. (Pubitemid 47538613)
43. Cangiano T, Liao J, Naitoh J, Dorey F, Figlin R, Belldegrun A. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J Clin Oncol. 1999;17:523-528. (Pubitemid 29075238)
44. Abel EJ, Culp SH, Stamatakis L, et al. Percutaneous primary tumor biopsy is unreliable to predict high risk pathologic features in patients with metastatic renal cell carcinoma. J Urol. 2009;181(1 suppl):501.